Computational design, synthesis, and assessment of 3-(4-(4-(1,3,4-oxadiazol-2-yl)-1H-imidazol-2-yl)phenyl)-1,2,4-oxadiazole derivatives as effective epidermal growth factor receptor inhibitors: a prospective strategy for anticancer therapy

Abstract

Herein, we developed innovative EGFR inhibitor using the FBDD approach. Compound 30a emerged as highly potent, selective, capable of arresting the cell cycle, and inducing apoptosis, underscoring its potential as a novel anticancer therapeutic agent.